Common Antidepressant Found to Reduce Methamphetamine Use in Promising New Study
Methamphetamine – more commonly known as meth, crystal, or ice – is a highly addictive, stimulant drug.
Methamphetamine, widely known as meth, crystal, or ice, is one of the most addictive and destructive stimulant drugs in the world. With limited treatment options available, researchers have long sought effective pharmacological interventions to help users reduce or quit their consumption.
A new study has found that bupropion, a common antidepressant also marketed under the brand name Wellbutrin and used as a smoking cessation aid, may significantly help people cut back on methamphetamine use. The findings represent a notable breakthrough in addiction medicine, where effective drug-based treatments have historically been scarce.
Researchers observed that participants who received bupropion alongside behavioral counseling showed measurably greater reductions in meth use compared to those who received a placebo. The drug is believed to work by targeting the brain's dopamine and norepinephrine systems, which are heavily disrupted by methamphetamine addiction.
Methamphetamine use has surged in recent years, contributing to rising overdose deaths and significant public health burdens across North America, Australia, and parts of Asia. Unlike opioid addiction, which has FDA-approved medications such as methadone and buprenorphine, meth addiction has lacked comparable pharmacological treatments — making this discovery particularly significant.
Experts caution that bupropion is not a silver bullet and works best as part of a comprehensive treatment program that includes behavioral therapy and support services. Side effects and individual responses to the medication will require careful monitoring by healthcare professionals.
Medical authorities and addiction specialists are calling for larger clinical trials to confirm the findings and establish standardized treatment protocols. If validated at scale, bupropion could become a widely accessible and affordable frontline option for treating methamphetamine use disorder, given that it is already approved and relatively low-cost.